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p38α MAPK regulates proliferation 
and differentiation of osteoclast 
progenitors and bone remodeling in 
an aging-dependent manner
Qian Cong1,2,*, Hao Jia2,3,*, Ping Li1,2, Shoutao Qiu1,2, James Yeh2, Yibin Wang4,  
Zhen-Lin Zhang2, Junping Ao5, Baojie Li1,2 & Huijuan Liu1,2
Bone mass is determined by the balance between bone formation, carried out by mesenchymal stem 
cell-derived osteoblasts, and bone resorption, carried out by monocyte-derived osteoclasts. Here we 
investigated the potential roles of p38 MAPKs, which are activated by growth factors and cytokines 
including RANKL and BMPs, in osteoclastogenesis and bone resorption by ablating p38α MAPK 
in LysM+monocytes. p38α deficiency promoted monocyte proliferation but regulated monocyte 
osteoclastic differentiation in a cell-density dependent manner, with proliferating p38α−/− cultures 
showing increased differentiation. While young mutant mice showed minor increase in bone mass, 
6-month-old mutant mice developed osteoporosis, associated with an increase in osteoclastogenesis 
and bone resorption and an increase in the pool of monocytes. Moreover, monocyte-specific p38α 
ablation resulted in a decrease in bone formation and the number of bone marrow mesenchymal stem/
stromal cells, likely due to decreased expression of PDGF-AA and BMP2. The expression of PDGF-AA 
and BMP2 was positively regulated by the p38 MAPK-Creb axis in osteoclasts, with the promoters of 
PDGF-AA and BMP2 having Creb binding sites. These findings uncovered the molecular mechanisms 
by which p38α MAPK regulates osteoclastogenesis and coordinates osteoclastogenesis and 
osteoblastogenesis.
Osteoporosis is a common disorder caused by enhanced bone resorption, decreased bone formation, or both1–3. 
The bone undergoes constant remodeling, with old bone being resorbed by osteoclasts and new bone formed 
by osteoblasts4. Osteoblasts are derived from mesenchymal stem/stromal cells (MSCs), which are defined by 
lineage-specific transcription factors Runx2 and Osterix5–7, while osteoclasts are derived from the hematopoie-
tic stem cell-monocyte lineage, which requires transcription factors such as PU.1, NF-κ B, c-Fos, and NFATc18. 
How differentiation of osteoclasts and osteoblasts from their respective progenitors is regulated remains not fully 
understood.
Bone formation and resorption are coupled via complex mechanisms. MSCs and osteoblasts have been shown 
to synthesize and secrete M-CSF, RANKL, and OPG to regulate osteoclast differentiation from monocytes, with 
the ratio of RANKL to OPG determining the yield of osteoclasts9–11. Moreover, some of the osteogenic regulators, 
e.g., TGFβ 1 and IGF1, are synthesized by osteoclasts and/or released from bone matrix during bone resorp-
tion12–15. While how MSCs/osteoblasts regulate osteoclastogenesis has been extensively studied, much less is 
known about how monocytes regulate osteoblastogenesis.
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p38 MAPKs are activated by many cytokines and growth factors, some of which are important regulators of 
bone modeling and remodeling, e.g., RANKL,TGFβ 1, BMPs, and TNFα 16–19. p38 MAPKs have been shown to 
play important roles in MSC osteoblast commitment and maturation as well as proliferation20–22. In addition, p38 
MAPKs can be activated by estrogen in MSCs, which controls the expression of OPG to regulate osteoclastogene-
sis and bone resorption23. However, the physiological roles of p38 MAPKs in osteoclastogenesis and bone resorp-
tion are less understood. RANKL activates p38 MAPKs via Rack1, Tak1, and MKK3/624,25. Tak1 and MKK3/6 
have been shown to play positive roles in osteoclast proliferation, differentiation, and/or survival26–29. Inhibitor 
or siRNA-based studies suggest that p38 MAPKs also play a positive role in RANKL-induced osteoclast differen-
tiation30–32. Using a transgenic mouse line that overexpresses TNFα , several studies have shown that p38 MAPKs 
are involved in inflammation-induced bone loss, by controlling IL-1 expression and osteoclast differentiation32–35. 
Yet there is still a lack of genetic evidence whether p38 MAPKs play an important role in osteoclastogenesis from 
its progenitors under physiological conditions.
Here we ablated p38α , the essential p38 isoform, in monocytes using a LysM-Cre mouse line17,36,37, and found 
that p38α ablation increased monocyte proliferation but could stimulate or inhibit monocyte osteoclastic differ-
entiation depending on cell density and the proliferation status. Phenotypically, the mutant mice showed a minor 
increase in bone mass at 2.5 month of age but develop osteoporotic phenotypes at 6 month of age. The modest 
increase in bone mass in young mice is associated with a decrease in the number of osteoclasts and bone resorp-
tion rate, which can only be explained by compromised osteoclast differentiation. The decrease in bone mass in 
6-month-old mice is associated with an increase in the number of osteoclasts and bone resorption rate, due to 
an expansion of the monocyte pool and likely enhanced osteoclast differentiation. Furthermore, p38α deficiency 
in LysM+  progenitors/osteoclasts suppressed the synthesis of PDGF-AA and BMP2, leading to a defect in MSC 
proliferation and differentiation and decreased bone formation. Mechanistic studies show that p38α regulates 
PDGF-AA and BMP2 expression in osteoclasts via Creb, which have multiple binding sites in the promoters of 
these two genes. Our findings collectively suggest that p38α plays important roles in osteoclastogenesis by coor-
dinating monocyte proliferation and differentiation and in coupling osteoclastogenesis and osteoblastogenesis.
Results
p38α deficiency promoted monocyte proliferation. To test whether p38α plays a role in osteoclas-
togenesis in vivo, we ablated p38α with a LysM-Cre mouse line, which has been used to study monocytes, the 
osteoclast progenitors38,39. Western blot analysis revealed that the protein levels of p38α in monocyte cultures 
derived from LysM-Cre; p38α f/f mice were about 8% of those of wild type cells (Fig. 1A), suggesting that more 
than 90% of the cells had p38α deletion. p38α deficiency increased the proliferation of ex vivo monocytes, judged 
by an increase in the number of total cells and Ki67 positive S phase cells in cultures (Fig. 1B and C), which were 
associated with a decrease in p53, p21, and p16 (Fig. 1D), negative regulators of cell proliferation that are reg-
ulated by p38 MAPKs36. On the other hand, the number of apoptotic cells in the cultures was not significantly 
altered by p38α deficiency (Supplementary Fig. S1A).
p38α could positively or negatively regulate osteoclast differentiation. We then compared 
the differentiation potential of p38α deficient monocytes isolated from 2.5-month-old mice. We found that in 
response to M-CSF and RANKL, p38α deficiency either stimulated or impeded osteoclast differentiation depend-
ing on the cell densities. When plated at a low density, p38α deficient monocyte cultures showed an increase 
in the number of TRAP positive osteoclasts (Fig. 2A), and an increase in the mRNA levels of PU.1, c-Fos, and 
NFATc1, transcription factors required for osteoclastogenesis (Fig. 2B). However, when plated at a high density, 
p38α deficient monocyte cultures showed a modestly decreased number of TRAP positive osteoclasts and a 
decrease in the mRNA levels of c-Fos and NFATc1 (Fig. 2A and C). Note that at high cell densities, osteoclasts 
appeared to be smaller than the ones in low-density cultures, suggesting that the limit of space may have inter-
fered with osteoclast growth and/or differentiation, which warrants further investigation. Moreover, since cells 
at high densities do not usually have space to proliferate, these results also suggest that p38α ’s roles in regulating 
early osteoclast differentiation may be linked to its effects on cell proliferation.
We found that p38α deficient monocyte cultures, at a low density, showed an increase in the protein levels 
of p50/52 and p65 isoforms of NF-κ B, potent stimulators of osteoclast differentiation, and enhanced activation 
of Tak1, an upstream activator of NF-κ B (Fig. 2D), enhanced Erk activation, which can be activated by Tak1 
(Fig. 2D). Previous studies have shown that p38 MAPKs phosphorylate Tab1/2 to inhibit Tak1 activation36,40, and 
Tak1 plays a positive role in osteoclast proliferation, differentiation, and survival26–29. It is likely that enhanced 
Tak1 activation may mediate the effects of p38α deficiency on osteoclastogenesis. Indeed, we found that inhibi-
tion of Tak1 with 5Z-7-Oxozeaenol down-regulated NF-κ B molecules and impeded osteoclast differentiation of 
p38α deficient and WT monocytes (Fig. 2E). These results suggest that p38α deficiency promoted osteoclastogen-
esis via hyperactivating Tak1 and NF-κ B at low cell densities.
However, at a high cell density, p38α deficiency did not affect Tak1 activation or the p65 isoform of NF-κ B, 
although it led to a decrease in the protein levels of c-Fos and phospho-c-Fos and an increase in p50/52 NF-κ B 
(Fig. 2F). These results suggest that Tak1 and NF-κ B may not be involved in regulating osteoclast differentia-
tion in high density cultures. Instead, down-regulation of c-Fos may contribute to the modest suppression of 
osteoclast differentiation caused by p38α deficiency. In addition, we found that when the same number of dif-
ferentiated osteoclasts were plated on dentine slices, p38α deficiency did not show an effect on in vitro oste-
oclast bone resorption activity (Fig. 2G), consistent with previous reported results30. Moreover, although p38 
MAPK-mediated expression of DC-Stamp has been shown to mediate vitamin E-induced osteoclast fusion41, 
we did not find an alteration in DC-Stamp expression and osteoclast fusion in the absence of p38α (Fig. 2A and 
Supplementary Fig. S1B).
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The above findings suggest that effect of p38α deficiency on osteoclast differentiation may be related to its 
effects on cell proliferation. Moreover, p38α deficiency only caused a modest effect on osteoclast differentia-
tion in high cell density cultures, this is inconsistent with previous studies reporting that small molecule com-
pound p38 MAPK inhibitors such as SB203580 greatly inhibited osteoclast differentiation30,42. We repeated the 
inhibitor experiment in high density monocyte cultures and found that the commonly used p38α /β inhibi-
tor SB203580 inhibited differentiation of not only WT but also p38α deficient osteoclasts, to similar extents 
(Supplementary Fig. S2). Since SB203580 inhibits both p38α and p38β , we tested whether p38β played a role in 
osteoclast differentiation. p38β was expressed in osteoclasts, yet knockdown of p38β did not significantly affect 
osteoclast differentiation in WT or p38α deficient monocytes (Supplementary Fig. S3A and S3B). Although 
it is possible that this result is caused by SB203580 targeting the leftover p38α MAPKs in LysM-Cre; p38α f/f 
monocytes, our observation that more than 90% of the monocytes had p38α deletion (Fig. 1A) argues against 
it. Instead, SB203580 may target other kinases besides p38α /β MAPKs and that the roles of p38α /β in osteoclast 
differentiation are not as great as previously thought.
Figure 1. p38α deficiency promoted monocyte proliferation and osteoclast differentiation. (A) Western 
blot results showed that p38α was deleted in the monocyte cultures of the LysM-Cre; p38α f/f mice. Bone marrow 
monocytes were isolated from mutant and control mice, cultured in the presence of M-CSF and RANKL for 
2 days, and then used for western blot analysis. (B) p38α deficient monocytes showed increased proliferation. 
Bone marrow monocytes were isolated from the mutant and control mice, plated at the same number, cultured 
in the presence of M-CSF/RANKL, and counted at different time points. N = 3. (C) p38α deficiency increased 
cell proliferation in monocyte cultures. WT and p38α deficient monocytes were induced to differentiate by 
M-CSF/RANKL. At day 2, these cells were immunostained for Ki67 to detect S phase cells (left panel). The ratios 
of Ki67 positive cells to DAPI-stained cells were presented (right panel). Scale bar, 50 μ m. N = 3. (D) Western 
blot analysis of extracts of cells described in Fig. 1A revealed that p38α deficient monocyte cultures showed a 
decrease in the levels of anti-proliferation proteins p53, p21, and p16. For all results in Fig. 1, P-values are based 
on Student’s t-test. *p < 0.05, **p < 0.01 when the value of mutant mice or cells was compared to that of control 
mice or cells.
www.nature.com/scientificreports/
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Figure 2. p38α regulated osteoclast differentiation in a cell density-dependent manner. (A) TRAP staining 
showed that p38α deficiency promoted osteoclast differentiation in low cell density culture but slightly inhibited 
osteoclast differentiation in high cell density cultures. Monocytes were isolated from LysM-Cre; p38α f/f and 
control mice, plated at different densities, and cultured in the presence of RANKL and M-CSF. After 7 days, the 
cultures were stained for TRAP (left panels). Right panels: quantitation data. Scale bar, 200 μ m. N = 3.  
(B) Quantitative PCR results showed that p38α deficiency promoted the expression of genes required for 
osteoclast differentiation at low cell densities. Monocytes described in Fig. 2A (low cell density) were collected 
and used to isolate total RNA, which was used to run quantitative PCR assays. N = 3. (C) Quantitative 
PCR results showed that p38α deficiency slightly inhibited the expression of genes required for osteoclast 
differentiation at high cell densities. (D) Western blot results showed that p38α deficient monocytes cultures 
at low densities exhibited an increase in activation of Tak1 and the protein levels of NF-κ B isoforms p50/52 
and p65. Scale bar, 100 μ m. (E) Inhibition of Tak1 down-regulated NF-κ B levels and suppressed osteoclast 
differentiation. Left panel: western blot showed that Tak1 inhibitor down-regulated NF-κ B levels. Middle panel: 
www.nature.com/scientificreports/
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LysM-Cre; p38αf/f mice developed osteoporotic phenotypes at 6 month of age. To test whether 
p38α ablation affected osteoclastogenesis and bone remodeling in vivo, we analyzed the bone parameters of 
mutant and age-matched control mice. The mutant mice were born at expected Mendelian frequency, with nor-
mal body size and limb length (Supplementary Fig. S4A and S4B). Micro-CT analysis revealed that at 2.5 month 
of age, the mutant mice showed a minor increase (less than 10%) in BMD and bone volume, without affecting 
trabecular bone number and thickness or cortical bone BMD and bone volume (Fig. 3A–C). Bone histomor-
phometry analysis confirmed that the mutant mice showed a minor increase in bone volume without affecting 
trabecular bone number, thickness, or separation (Supplementary Fig. S5A and S5B).
However, micro-CT analysis revealed that 6-month-old mutant mice showed osteoporotic phenotypes, with 
a decrease (about 30%) in BMD, bone volume, trabecular bone number, and trabecular bone thickness, as well 
as an increase in trabecular separation (Fig. 3D–F). The bone histomorphometric results confirmed that the 
6-month-old mutant mice showed a decrease in bone volume, trabecular bone number, trabecular bone thick-
ness, and an increase in trabecular separation (Supplementary Fig. S5C and S5D). These results suggest that p38α 
expressed in monocytes and osteoclasts regulate bone remodeling in an age-dependent manner.
Bone resorption in LysM-Cre; p38αf/f mice was increased at 6 month of age. Histomorphometry 
analysis showed that the modest increase in bone mass in 2.5-month-old mice was associated with a decrease 
in bone resorption (Fig. 4A). The bone erosion surfaces and the number of osteoclasts per bone surface were 
decreased (Fig. 4A). In addition, the levels of urine DPD, an in vivo marker of bone resorption, was also decreased 
(Fig. 4A). The decrease in the number of osteoclasts could only be explained by compromised differentiation of 
osteoclasts, as p38α deficiency promoted monocyte proliferation.
On the other hand, the osteoporotic phenotypes of 6-month-old LysM-Cre; p38α f/f mice were associated with 
an increase in bone resorption (Fig. 4B). The erosion surface, the number of osteoclasts per bone surface, and the 
levels of urine deoxypyridinoline (DPD) were all increased compared to the age-matched control mice (Fig. 4B). 
This could be explained by increased monocyte proliferation, increased osteoclast differentiation, or both. To val-
idate this finding, we stained tibia bones of 2.5 and 6-month-old LysM-Cre; p38α f/f and WT mice for TRAP, and 
found that TRAP staining was slightly decreased in 2.5 month of age (Fig. 4C), but greatly increased at 6 month of 
age, in the mutant mice (Fig. 4D). These results suggest that ablation of p38α affects osteoclastogenesis and bone 
resorption in an age-dependent manner.
LysM-Cre; p38αf/f mice showed an increased monocyte pool at 6 month of age. How does p38α 
deficiency dissimilarly affect osteoclastogenesis at different ages? To test whether age difference altered osteoclast 
differentiation potential, we isolated primary monocytes from 6-month-old LysM-Cre; p38α f/f and control mice. 
These p38α deficient monocytes, like those isolated from 2.5-month-old mice (Fig. 2), showed increased prolif-
eration in vitro compared to control monocyte cultures (Supplementary Fig. S6A). At low densities, p38α defi-
ciency promoted osteoclast differentiation, whereas at high densities, p38α deficiency slightly inhibited osteoclast 
differentiation (Supplementary Fig. S6B). In addition, p38α deficiency did not affect bone resorption activity of 
osteoclasts on dentine slices (Supplementary Fig. S6C). Thus, monocytes isolated from 2.5- or 6-month-old mice 
displayed similar proliferation and differentiation behaviors in vitro.
Since p38α deficiency promotes monocyte proliferation, we compared the numbers of bone marrow mono-
cytes between LysM-Cre; p38α f/f and age-matched control mice. Bone marrow monocytes can be labeled by 
Gr1lowCD11b+ 43. Flow cytometry analysis revealed that the percentage of monocytes in bone marrow was 
increased in 6-month-old LysM-Cre; p38α f/f mice compared to the age-matched control mice (Fig. 5A). The per-
centage of bone marrow monocytes were also increased in 2.5-month-old LysM-Cre; p38α f/f mice, yet to a much 
lesser extent than 6 month-old mice (Fig. 5B).
The greater increase in the number of bone marrow monocytes in 6-month-old mouse may reflect accumula-
tion of overproliferating p38α deficient monocytes over time. Interestingly, comparison of p38 MAPK activation 
in monocytes isolated from 2.5 and 6-month-old normal mice revealed that p38 MAPK activation was enhanced 
in monocytes of the older mice (Fig. 5C). Since monocytes isolated from 2.5- or 6-month-old mice showed sim-
ilar behaviors in vitro (Supplementary Fig. S6), we suspect that the difference might be attributable to environ-
mental changes in older mice. An increase in p38 MAPK activation in older mice has been reported in a few other 
tissues, which may reflect the accumulation of stress44,45. Enhanced p38 MAPK activation may restrict monocyte 
proliferation in older mice to a greater extent than that in young mice; p38α deficiency may relieve this restriction 
and lead to greater expansion of monocytes in older mice than in young mice. The growth difference caused by 
p38α ablation at different ages may contribute to the difference in osteoclast differentiation (Fig. 2).
LysM-Cre; p38αf/f mice showed a decrease in bone formation. Histomorphometry analysis also 
revealed that in 2.5- or 6-month-old mutant mice, the bone formation rate, mineral apposition rate, and the 
Tak1 inhibitor suppressed osteoclast differentiation. Right panel: Quantitation data. N = 3. (F) Western blot 
results revealed that p38α deficient monocyte cultures at high densities showed a decrease in c-Fos protein 
levels. (G) p38α deficiency did not affect the resorbing activity of osteoclasts on dentine slices. WT and p38 
deficient monocytes were induced to differentiate into osteoclasts by M-CSF and RANKL for 2 days and then 
counted and the same numbers of cells were plated onto dentine slices. After 7 days, the dentine slices were 
sonicated and stained with Gill’s hematoxylin. Right panel: quantitation data. Scale bar, 200 μ m. N = 3. For all 
results in Fig. 2, P-values are based on Student’s t-test. *p < 0.05, **p < 0.01 when the value of mutant mice or 
cells was compared to that of control mice or cells, or the drugs-treated group compared to control group.
www.nature.com/scientificreports/
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number of osteoblasts were all decreased compared to age-matched control mice (Fig. 6A and B). Since LysM 
does not label MSCs or osteoblasts, these results suggest that p38α deficiency may indirectly affect osteoblast 
proliferation and differentiation, for instance, by affecting the expression and secretion of coupling factors. We 
Figure 3. Micro-CT results revealed that LysM-Cre; p38αf/f mice developed osteoporotic phenotypes at 
6 month of age. (A) A representative μ CT image of the femur bones of 2.5 month-old LysM-Cre; p38α f/f and 
control mice. (B) Two and half-month-old LysM-Cre; p38α f/f mice, compared to control mice, showed a minor 
increase in bone mineral density in the femur trabecular bones. N = 8. (C) Two and half-month-old LysM-
Cre; p38α f/f mice only showed a minor increase in BV/TV and a decrease in trabecular separation, but not a 
change in trabecular number or thickness compared to control mice. N = 8. (D) A representative μ CT image 
of the femur bones of 6 month-old LysM-Cre; p38α f/f and control mice. (E) Bone mineral density of the femur 
trabecular bones of 6 month-old LysM-Cre; p38α f/f and control mice. N = 8. (F) Six-month-old LysM-Cre;  
p38α f/f mice showed a decrease in BV/TV, trabecular number, trabecular thickness, and an increase in 
trabecular separation compared to control mice. N = 8. For all results in Fig. 3, P-values are based on Student’s 
t-test. *p < 0.05, **p < 0.01 when the value of mutant mice was compared to that of control mice.
www.nature.com/scientificreports/
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also compared the number of bone marrow ALP positive CFUs in LysM-Cre; p38α f/f and normal control mice, 
which is an indication of the number of MSCs, and found that p38α ablation in monocytes and osteoclasts led to 
a significant decrease in the number of MSCs in 2.5 or 6-month-old mice (Fig. 6C and D). These results suggest 
that p38α may regulate osteoclast synthesis and secretion of growth factors to regulate MSC proliferation and/
or differentiation.
p38α deficient monocytes show reduced capacity in supporting MSC differentiation. We then 
carried out co-culture experiments of MSCs and monocytes to test whether ablation of p38α in monocytes had 
an effect on MSC differentiation. WT MSCs were plated first and 24 hrs later, monocytes were plated on top of 
the MSC layer. After 4 days, the suspension cells were washed off and the cell culture plates were stained for ALP, 
a marker of osteoblast differentiation. We found that p38α deficient monocytes and osteoclasts showed a reduced 
Figure 4. LysM-Cre; p38αf/f mice showed distinct alterations in bone resorption at 2.5 and 6 month of age. 
(A) Two and half-month-old LysM-Cre; p38α f/f mice showed a slight decrease in erosion surface, osteoclast 
surface, osteoclast number, and urine DPD levels compared to control mice. N = 8. (B) Six-month-old LysM-
Cre; p38α f/f mice showed an increase in erosion surface, osteoclast surface, osteoclast number, and urine DPD 
levels compared to control mice. N = 8. (C) In vivo TRAP staining showed that the femur bones of 2.5-month-
old LysM-Cre; p38α f/f mice exhibited a minor decrease in osteoclasts compared to control mice. Scale bar,  
200 μ m. N = 3. (D) In vivo TRAP staining showed that the femur bones of 6-month-old LysM-Cre; p38α f/f mice 
exhibited an increase in osteoclasts compared to control mice. Scale bar, 50 μ m. N = 3. For all results in Fig. 4, 
P-values are based on Student’s t-test. **p < 0.01 when the value of mutant mice or cells was compared to that of 
control mice.
www.nature.com/scientificreports/
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capacity in supporting MSC osteogenic differentiation, in the presence or absence of RANKL/M-CSF (Supplemen
tary Fig. S7A and S7B). Moreover, the culture medium of p38α deficient monocytes also showed a lower capacity 
in supporting MSC osteogenic differentiation than the medium of WT osteoclast cultures (Fig. 7A). These results 
suggest that p38α deficient osteoclasts may secrete a reduced amount of a pro-osteogenic differentiation factor.
p38α regulated BMP2/PDGF-AA expression via Creb in monocytes and osteoclasts. To identify 
the growth factors or cytokines secreted by monocytes and/or osteoclasts, we tested whether p38α deficiency 
altered the expression of the cytokines and growth factors that have been reported to couple osteoclastogen-
esis and osteoblastogenesis including Ephrin B2, Cthrc1, LIF, IL6, IL11, Wnt10B, TGFβ 1, IGF1, PDGF-AA, 
PDGF-BB, BMP2, BMP6, and BMP412. Quantitative PCR analysis showed that p38α deficient monocytes 
expressed greatly reduced levels of BMP2 and PDGF-AA, modestly reduced TGFβ 1 and IGF1, but not other mol-
ecules tested (Fig. 7B and Supplementary Fig. S8A). Moreover, bone extracts also showed a decrease in BMP2 and 
PDGF-AA mRNA levels when p38α is deleted in osteoclasts (Fig. 7C). In the course of osteoclast differentiation, 
PDGF-AA was slightly up-regulated before the expression of TRAP, whereas BMP2 was up-regulated after TRAP 
expression (Fig. 7D). Decreased PDGF-AA expression may contribute to the decrease in the number of MSCs 
Figure 5. LysM-Cre; p38αf/f mice showed an increase in the size of monocyte pool. (A) The number of 
the bone marrow Gr1lowCD11b+ monocytes was increased in 6 month-old LysM-Cre; p38α f/f mice compared 
to control mice. N = 3. (B) The number of the bone marrow Gr1lowCD11b+ monocytes was increased in 2.5 
month-old LysM-Cre; p38α f/f mice compared to control mice, to a lesser extent than that of 6-month-oldmice. 
N = 3. (C) Western blot showed that p38 MAPK activation was enhanced in the bone marrow monocytes 
isolated from 6-month-old normal mice compared to that of 2.5-month-old mice. BM cells were flushed out 
of the bones and purified with the Percoll method at 4 oC, which were directly used for western blot analysis. 
Results from two pairs of mice were shown. For all results in Fig. 5, P-values are based on Student’s t-test. 
*p < 0.05, **p < 0.01 when the value of mutant mice was compared to that of control mice.
www.nature.com/scientificreports/
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in LysM-Cre; p38α f/f mice. Moreover, addition of BMP2 rescued the decreased osteogenic differentiation of WT 
MSCs co-cultured with p38α deficient monocytes (Fig. 7E). On the other hand, TGFβ 1 and IGF1 were expressed 
at low levels (required > 40 PCR cycles to detect) in monocytes or osteoclasts and were not affected by osteoclast 
differentiation stages (Supplementary Fig. S8B and S8C).
Figure 6. LysM-Cre; p38αf/f mice showed a decrease in bone formation at 2.5 or 6 month of age. (A) Two 
and half-month-old LysM-Cre; p38α f/f mice showed a decrease in BFR, MAR, and the number of osteoblasts per 
bone surface compared to control mice. N = 8. (B) Six-month-old LysM-Cre; p38α f/f mice showed a decrease 
in BFR, MAR, and the number of osteoblasts per bone surface compared to control mice. N = 8. (C) Two and 
half-month-old LysM-Cre; p38α f/f mice showed a decrease in the number of bone marrow colony forming units 
compared to control mice. Upper panel: ALP staining. Bottom panel: quantitation data. N = 3. (D) Six-month-
old LysM-Cre; p38α f/f mice showed a decrease in the number of bone marrow colony forming units compared 
to control mice. Upper panel: ALP staining. Bottom panel: quantitation data. N = 3. For all results in Fig. 6, 
P-values are based on Student’s t-test. *p < 0.05, **p < 0.01 when the value of mutant mice or cells was compared 
to that of control mice or cells.
www.nature.com/scientificreports/
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Figure 7. Ablation of p38α in monocytes promoted osteoblastogenesis by promoting BMP2/PDGF-AA 
synthesis via Creb. (A) p38α deficient monocyte culture medium showed a reduced activity in supporting 
osteogenic differentiation of normal MSC cells. Normal MSCs were plated and 24 hrs later, culture medium of WT 
or p38α deficient monocytes (in the absence of RANKL/M-CSF) was added to the cultures. Four days later, the 
plates were stained for ALP. Bottom panel: quantitation data of ALP. N = 3. (B) Quantitative PCR results showed 
that p38α deficient monocytes exhibited a decrease in the mRNA levels of BMP2 and PDGF-AA compared to 
control cells. N = 3. (C) Quantitative PCR assays revealed that the bone extracts of LysM-Cre; p38α f/f mice showed 
a decrease in the mRNA levels of PDGF-AA and BMP2 compared to control mice. N = 3. (D) Expression of 
PDGF-AA, BMP2 and TRAP during osteoclast differentiation. The WT monocytes were induced to differentiate 
by M-CSF/RANKL. The cells were harvested at different times of induction and total RNA was isolated from these 
cells, which was used to perform quantitative PCR assays. The basal levels of PDGF-AA mRNA were set at 1.0 and 
the relative amounts of BMP2 and TRAP were normalized to that of PDGF-AA. (E) Addition of BMP2 to the co-
culture system of WT MSCs and p38α deficient monocytes enhanced osteoblast differentiation, justified by ALP 
staining. Bottom Panel: ALP quantitation data. N = 3. (F) Western blot results show that p38α deficient monocytes 
displayed a decrease in the levels of p-Creb compared to WT cells. (G) Knockdown of Creb with siRNA led to 
down-regulation of PDGF-AA and BMP2 expression in normal monocytes. Upper panel: western blot showing 
the knockdown of Creb. Bottom panel: quantitation data. N = 3. (H) Chromatin-IP experiments showed that 
PDGF-AA promoter had two Creb binding sites and BMP2 promoter had one Creb binding sites. Right panel: 
diagrams showing the binding sites of Creb in the promoters of PDGF-AA and BMP2 genes. N = 3. For all results 
in Fig. 7, P-values are based on Student’s t-test. **p < 0.01 when the mutant mice were compared to control mice, 
or Creb knockdown cells were compared to the control cells.
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To identify the transcription factors downstream of p38α that regulate the expression of PDGF-AA and 
BMP2, we knocked down each of the well-studied transcription factors in RAW264.3 cells and looked at their 
effect on the mRNA levels of PDGF-AA and BMP2 (data not shown). We found that Creb appeared to medi-
ate the p38α ’s effect on BMP2 and PDGF-AA expression. Western blot showed that Creb phosphorylation was 
reduced in p38α deficient monocytes and osteoclasts (Fig. 7F). Knockdown of Creb with siRNA in osteoclasts led 
to a decrease in the mRNA levels of PDGF-AA and BMP2 (Fig. 7G). ChIP assays showed that there were 2 Creb 
binding sites in PDGF-AA promoter and 1 binding site in BMP2 promoter (Fig. 7H). These results collectively 
suggest that osteoclasts utilized the p38α -Creb axis to regulate the expression of PDGF-AA and BMP2 to further 
influence MSC proliferation and differentiation.
Discussion
p38 MAPKs can be activated by growth factors and cytokines, some of which, e.g., BMPs, TGFβ , and RANKL, 
play important roles in bone development and remodeling. In the MSC-osteoblast lineage, p38 MAPKs are found 
to promote MSC osteogenic commitment and osteoblast maturation by suppressing the NF-κ B pathway and 
phosphorylating Runx220,37,46. In addition, p38 MAPKs in Prx1-labeled MSCs appear to regulate the expression 
of OPG, which regulates bone mass accrual under physiological and pathological conditions23. However, the 
physiological functions of p38α in the monocyte-osteoclast lineage and bone resorption are not well understood. 
In this study, we ablated p38α in LysM-labeled monocytes and found that p38α inhibits monocyte proliferation 
and regulates osteoclastic differentiation in a cell density/proliferation-dependent manner. It also controls the 
expression of PDGF-AA and BMP2 in osteoclasts to affect osteoblastogenesis and bone formation. The coordi-
nated actions of p38α in monocytes may be needed to maintain optimal bone mass. Disruption of p38α resulted 
in osteoporotic phenotypes at 6 month of age in mice while younger mice showed a minor increase in bone mass. 
This study thus provides genetic evidence that p38α plays complex roles in osteoclastogenesis, which are affected 
by the age of mice, and in coupling osteoclastogenesis and osteoblastogenesis.
Osteoclastogenesis is a multi-step process that includes expansion of the progenitors, commitment to osteo-
clasts, and cell fusion. p38α deficiency leads to enhanced monocyte proliferation, likely due to a reduction in the 
cyclin-dependent kinase inhibitors p16 and p21 as well as tumor suppressor p53, and an expansion of the bone 
marrow monocyte pool, especially in old mice. Moreover, we show for the first time that p38α affects in vitro oste-
oclast differentiation in a cell density dependent manner, which may be related to the proliferation status of the 
cells. In low cell density cultures, p38α deficiency promotes osteoclast differentiation, whereas in high cell density 
cultures, p38α deficiency mildly inhibits osteoclast differentiation. It has been reported that cell proliferation 
plays a positive role in promoting osteoclast differentiation47–49. In addition, p38α has been shown to play a role in 
sensing cell density and determines myoblast differentiation50,51. Moreover, low density cultures of p38α deficient 
monocytes showed an increase in Tak1 activation and NF-κ B protein levels, whereas high density culture showed 
normal Tak1 activation. These results suggest that the density-dependent effect of p38α deficiency may be related 
to the proliferation potential that involves Tak1 activation, which warrants further investigation. Overall, our 
findings reveal much complex roles for p38α in osteoclastogenesis compared to the p38 MAPK inhibitor-based 
studies. Moreover, we also showed that p38β was expressed in the osteoclasts, yet it played a minor role in osteo-
clast differentiation.
Our genetic evidence suggests that p38α expressed in monocytes and osteoclasts coordinates osteoclastogen-
esis and osteoblastogenesis. When p38α is ablated in monocytes, bone formation is down-regulated regardless 
the age of the mice. p38α appears to regulate osteoclastogenesis-osteoblastogenesis coupling by controlling the 
expression of PDGF-AA and BMP2 in monocytes and osteoclasts via its downstream transcription factor Creb, 
which binds to the promoters of these two genes. Interestingly, monocytes, even in the absence of RANKL/M-CSF, 
synthesize PDGF-AA. Moreover, monocyte appears to express stage-specific coupling factors that have different 
effects on MSC proliferation and differentiation. The orderly expression of PDGF-AA and BMP2 by monocytes 
and osteoclasts may first facilitate MSC expansion and then osteogenic differentiation.
It has been long known that p38 MAPKs play an important role in promoting cell senescence and aging52–54. 
In some tissues, like bone marrow monocytes, an increase in the levels of p38 MAPK activation is associated with 
aging44,45,55. In this study, we found that p38 MAPKs are highly activated in monocytes of older mice compared to 
young mice, suggesting that p38α may display a stronger effect on osteoclastogenesis in old mice than in young 
mice and as such, p38 ablation may show more robust effects on monocyte proliferation and differentiation. This 
may be a reason why p38α deficient mice showed a great decrease in bone mass and developed osteoporosis at 6 
month of age, attributable to an increase in osteoclastogenesis and bone resorption. These findings suggest that 
p38α plays a role in osteoclastogenesis in an age-dependent manner.
In summary, the present study demonstrates that p38α plays complex roles in monocyte proliferation and 
osteoclast differentiation in cell-autonomous manner, and in coupling osteoclastogenesis and osteoblastogenesis. 
Moreover, p38 MAPK activation in monocytes appears to be regulated in an age-dependent manner, which con-
trols osteoclastogenesis by suppressing monocyte proliferation and differentiation and the size of the osteoclast 
progenitor pool. As such, p38α may mediate the effects of RANKL, BMPs, and other cytokines, on bone remod-
eling, and thus represent a drug target for osteoporosis therapy.
Materials and Methods
Mice and genotyping. The p38α f/f mouse line was generated in Dr. Yibin Wang’s laboratory at UCLA. The 
LysM-Cre mouse line was purchased from The Jackson Laboratories. All the mice were housed in the patho-
gen-free facility of Bio-X Institutes at Shanghai Jiao Tong University. The experimental protocols and methods 
were ratified by the Animal Welfare Committee of the University [SYXK(SH)2011-0112]. All experimental meth-
ods were performed in accordance with the approved guidelines. Two and half- or six-month-old male mice 
were used for in vivo and ex vivo analysis. The compared mice were of the same age and same gender (male). 
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Mice were anesthetized with Avertin (Sigma-Aldrich, St. Louis, USA) for blood sample collection. The animals 
were finally euthanized by cervical vertebra dislocation. Genotyping use the following sets of primers. p38αf/f -F: 
5′ -TCCTACGAGCGTCGGCAAGGTG-3′ ; p38αf/f -R: 5′ -AGTCCCCGAGAGTTCCTGCCTC-3′ ; and LysM-
Cre, oIMR3066: 5′ -CCCAGAAATGCCAGATTACG-3′ ; oIMR3067: 5′ -CTTGGGCTGCCAGAATTTCTC-3′ ; 
and oIMR3068: 5′ -TTACAGTCGGCCAGGCTGAC-3′ .
Bone histomorphometry. Bone histomorphometry analysis was based on previously described protocol56. 
Firstly, calcein was intraperitoneally injected twice at 0.1 mg/10 g body weight at 1 and 8 days before the mice are 
sacrificed. Four percent paraformaldehyde (PFA) was used to fix the femurs overnight, which were stored in 70% 
alcohol for future use. The bones were dehydrated in 90–100% ethanol overnight in vacuum, and then transferred 
into xylene overnight. The femurs were embedded with resin, sliced into 4 μ m sections, which were stained with 
Villanueva-goldner’s one step trichrome method. All bone-specific parameters were measured and expressed in 
units following the guidelines established by the American Society for Bone and Mineral Research histomorpho-
metry nomenclature committee using OsteoMeasure software (OsteoMetrics Inc, Decatur, GA).
Fixed and ethanol-dehydrated femur were scanned with a high-resolution μ CT (SkyScan1176 Software: 
Version 1.1 (build 6), Bruker, Kontich, Belgium). Data were acquired at 50 keV energy, 270 μ A current, and 0.2 mm 
filter for 8.96 μ m cubic resolutions. Three-dimensional reconstructions were generated with the following param-
eters: smoothing = 2, ring artifact correction = 8, minimum and maximum for CS to image conversion were 0 
and 0.088, and threshold was 75 (spongiosa) or 115 (cortex). 3D structural parameters were obtained (1.5 mm) 
for trabecular (secondary spongiosa) and (0.5 mm) for cortical bone in femur. We measured Bone Mineral 
Density (BMD, mg/cm3), bone volume/trabecular volume (BV/TV, %), trabecular separation (Tb.Sp, μ m), 
trabecular thickness (Tb.Th, μ m), trabecular number (Tb.N, mm−1).
Deoxypyridinoline Measurement. To evaluate bone resorption rate in vivo, urine Deoxypyridinoline 
(DPD) was determined with MicroVue (Quidel, San Diego, CA) assay kit following the protocol provided by the 
manufacturer. The final DPD values were normalized to the urine levels of creatine.
Bone marrow colony forming unit assay. To determine colony forming units (CFUs), red blood cells 
were lysed and the washed bone marrow cells were plated at 5 × 106 per well in 6-well plates. Three or four days 
later, complete α MEM medium with 10% FBS was changed and seven days later, the cells were fixed with 4% PFA 
for 30 min, and washed with PBS 3 times, then stained for ALP (Sigma-Aldrich, St. Louis, USA).
In vitro osteoclastogenesis assay and bone resorption assay. Mouse bone marrow cells were flushed 
out from the limbs. The monocyte fraction was isolated by centrifugation on a Percoll plus lymphocyte separation 
medium gradient (Sigma-Aldrich, St. Louis, USA). The monocytes were counted and seeded into 96-well plate at 
1 × 106/well with 25 ng/ml M-CSF and 50 ng/ml RANKL in completed α MEM medium. Five to seven days later, 
the cells were fixed and stained for TRAP using the Acid Phosphatase, Leukocyte TRAP Kit (Sigma-Aldrich, 
St. Louis, USA). The cells were photographed and TRAP positive multinucleated osteoclasts were counted 
(≥ 3 nuclei).
Osteoclast resorption function was assessed by a pit formation assay on dentine slices (IDS, Boldon, UK). 
Monocytes were pre-cultured for 2 days in the presence of 25 ng/ml M-CSF and 50 ng/ml RANKL in completed 
α MEM medium, counted, and plated onto dentine slices that were preincubated with serum for 2 hrs. After 7 
days, the dentine slices were sonicated in 0.5 M ammonium hydroxide, stained with Gill’s hematoxylin for 5 min, 
washed with water, and photographed under microscope. Then the resorbed areas were measured.
MSCs and monocytes Co-culture. Co-culture experiments were done according to previously-described 
protocols56. Firstly, MSCs were counted and plated in 24-well plates at 5 × 104 in the bottom. Twenty four hrs after 
cell adherence, monocytes or monocyte culture medium were added on top of the MSCs layer with or without 
RANKL/M-CSF in completed α MEM medium. Four to seven days later, the cells were fixed and stained for ALP.
Cell Transfection. Monocytes were plated and transfected with siRNA for Creb (Santa Cruz, sc-35111, 
California), p38β (Santa Cruz, sc-39117, California), and control siRNA (Santa Cruz, sc-37007, California) using 
Lipofectamine 2000 (Invitrogen, USA). Cells were harvested and knockdown efficiency was determined with 
western blot analysis.
Immunohistochemical staining and TUNEL assay. WT and p38α deficient monocytes were isolated 
and plated onto coverslips and were induced to enter differentiation process by M-CSF/RANKL. Cell prolifera-
tion and apoptosis were determined by Ki67 immunofluorescence staining (ab15580, Abcam, Cambridge, MA) 
and TUNEL assay (In Situ Cell Death Detection Kit Fluorescein, Roche, Basel, Switzerland) respectively.
TRAP staining. To decalcify the tibia bones, the bones were immersed in 10% Ethylene diamine tetracetic 
acid (EDTA) at room temperature, which was changed every 2 days and continued for 3-4 weeks. After samples 
were soft, 70% to 100% alcohol was used to dehydrate the samples. Then the bone samples were dealcoholised 
in xylene for 5 hrs. The tibia bones were embedded in paraffin and cut into 5 μ m sections. TRAP staining was 
carried out using Acid Phosphatase, Leukocyte TRAP Kit (387A, Sigma-Aldrich, St. Louis, USA) according to 
manufacturer’s protocol.
Flow cytometry. The bone marrow monocytes were isolated from mutant and WT mice, with red blood cells 
lysed, and were analyzed using flow cytometry (FACSCalibur, Becton Dickinson, USA) to quantify the percentage 
of Gr1lowCD11b+ monocytes.
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Cell proliferation assay. Cell number was assessed by CCK-8 assays. In brief, monocytes were plated at 
5 × 104/well into 96-well and cultured in the presence of 25 ng/ml M-CSF, up to 96 hrs. The CCK-8 was added 
to the cultures for 4 hours at 37 °C, and the cell numbers were determined by reading OD (optical density) at a 
wavelength of 450 nm using a microplate reader.
Western blot analysis. TNEN buffer were used to lyse cells in the presence of protease and phosphatase 
inhibitors. SDS-PAGE was used to analyze protein lysates. The specific antibodies used in this study were: NF-κ B 
p65 (Cell Signaling, 4767, Boston, MA), NF-κ B p50/52 (Santa Cruz, sc-8414, California), p38α MAPK (Cell 
Signaling, 9212, Boston, MA), p38β (Cell Signaling, 2339, Boston, MA), p-p38MAPK (T180/182) (Cell Signaling, 
9211, Boston, MA), p53 (c12) (Cell Signaling, 2524, Boston, MA), Tak1 (Cell Signaling, 4505, Boston, MA), 
p-Tak1(T184/187) (Cell Signaling, 4531, Boston, MA), Creb (Upstate, 05767, Boston, MA), p-Creb (Upstate, 
6519, Boston, MA), ERK (Cell Signaling, 9107, Boston, MA), p-ERK (Cell Signaling, 9106s, Boston, MA), cFos 
(Calbiochem, pc38, Darmstadt, Germany), p-cFos (Santa Cruz, sc-81485, California), and β -ACTIN (Santa Cruz, 
sc-81178, California).
Quantitative PCR. Cell or femur total RNA was extracted with Trizol reagent (Invitrogen, USA). cDNA was 
synthesized with Transcriptor First strand cDNA synthesis kit (Roche, Basel, Switzerland). Quantitative PCRs 
were carried out with FS Universal SYBR Green Master Premix (Roche, Basel, Switzerland). Endogenous GAPDH 
were used as an internal control. Quantitative PCR primers were listed in Supplementary Table S1.
Chromatin immunoprecipitation (ChIP) assays. ChIP assays were carried out following the protocol 
from SimpleChIP™ Enzymatic Chromatin IP Kit (Cell Signaling, 9002, Boston, MA). Osteoclasts (4x107) were 
treated with 1% formaldehyde for 10 min at room temperature to crosslink proteins to DNA, followed by the 
addition of glycine to stop the crosslinking. The cells were collected with a cell scraper and washed in ice-cold 
PBS. The chromatin was harvested and fragmented using enzymatic digestion. Briefly, resuspended cells were 
subjected to DNA shearing for 10 min at 37 °C. An aliquot of each sample was set aside as input control, while 
the remaining portion was subjected to immunoprecipitation with anti-Creb antibodies (Upstate, 05767, Boston, 
MA) overnight at 4 °C, with IgG (Beyotime, Jiangsu, China) as control. Immunoprecipitated complex was treated 
with protease and the DNA was amplified by PCR using primer pairs designed to amplify about 100 bp frag-
ments spanning the 2 kb BMP2 and PDGF-AA promoters. Aliquots were subjected to quantitative PCR using 
gene-specific primer sets that were listed in Supplementary Table S2.
Data analysis. At least eight pairs of mice were used for bone histomorphometry analysis. For ex vivo assays, 
cells from 3 mutant mice were individually tested, with triplicate for each mouse. For cell line-based assays, 
experiments were repeated three times with triplicate for each. Total 9 readouts were obtained and statistically 
analyzed. Results are presented as mean ± SEM. Statistical comparisons were performed using unpaired Student’s 
two tailed t test. P < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01 when mutant mice were 
compared to control mice, siRNA knockdown cells were compared to control cells.
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